Novartis Ag

Chiron Corporation

Glaxosmithkline Biologicals Sa

Novartis Vaccines and Diagnostics Srl

Chiron S.r.l.

Novartis Vaccines & Diagnostics, Gmbh

Seqirus UK Limited

J. Craig Venter Institute

Sclavo Spa

University System of Maryland

Eniricerche S.p.a.

Biocine S.p.a.

Gsk Vaccines S.r.l.

Statens Institutt for Folkehelse

Children's Hospital Oakland Research Institute

Rino Rappuoli

Mariagrazia Pizza

Vega Masignani

Guido Grandi

Maria Scarselli

Vincenzo Scarlato

Marzia Monica Giuliani

Cesira Galeotti

Claire M Fraser

Herve Tettelin

Marirosa Mora

Giuseppe Del Giudice

Erin Hickey

Giulio Ratti

Jeremy Petersen

J Craig Venter

Antonello Covacci

Massimo Bugnoli

Derek T O'Hagan

Susan Barnett

John Telford

Indresh K Srivastava

Victoria A Sharma

Giovanni Macchia

Antonella Bartoloni

Roberto Olivieri

Guilio Ratti

Barbara Capecchi

Alfredo Nicosia

Jan Zur Megede

Maria Rita Fontana

Maria Arico

Davide Serruto

Gail L Barchfeld

Steven Black

Natale Figura

Uwe Nicolay

Mariarosa Mora

Hervé Tettelin

Valentina Giannelli

Maria Beatrice Arico

Paolo Costantino

Alessio Fasano

Dan M Granoff

Gregory R Moe

Salvatore Toma

Francesco Norelli

Francesca De Ferra

Luciano Nencioni

Fabio Sabbatini

Barbara Riboli

Audino Podda

Paola Pedroni

Johan Holst

Michele Pallaoro

Craig Venter

Daniele Veggi

Wim Hol

Maria B Arico'

Beatrice Arico

Sergio Uzzau

Teresa De Magistris

Philipp Oster

Maria Rosa Mora

Giulo Ratti

Jeremy D Peterson

Craig Ventor

Maria Kontakou

Guiseppe Del Giudice

Lucia Tagliaferri

Stefano Viti

Antonella Giglioli

Mario Domenighini

Derek O'hagan

Mazia Monica Giuliani

Mariagratia Pizza

Enzo Scalato

Laura Ciucchi

Federica Di Marcello

Guiseppe Del Guidice

An immunogenic composition comprising: (i) a non-virion influenza virus antigen, prepared from a virus grown in cell culture; and (ii) an adjuvant. Preferred adjuvants comprise oil-in-water emulsions.

Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture

Disclosed herein are methods for enhancing immune responses to a vaccine in immunocompromised individuals, including those receiving a statin therapy. Related products are also provided.

Vaccination of immunocompromised subjects

An immunogenic composition comprising (i) a non-virion influenza virus antigen prepared from a virus grown in cell culture; and (ii) an adjuvant. Preferred adjuvants comprise oil-in-water emulsions.

H5N1 influenza viruses isolated from animals and humans since 2003 separate into distinct clades based on hemagglutinin amino acid sequences. According to the invention, multiple clades are used in influenza immunization. Thus there is a prime-boost immunization schedule where a subject receives a priming dose of a first clade of H5 influenza A virus and a boosting dose of a second clade of H5 influenza A virus. There is also an immunogenic composition comprising hemagglutinin antigens from more than one clade of H5 influenza A virus.

Vaccination with multiple clades of H5 influenza A virus

International patent application WO99/61053 discloses immunogenic compositions that compriseserogroup C oligosaccharide conjugated to a carrier, in combination withserogroup B outer membrane protein. These are disclosed in the present application in combination with further Neisserial proteins and/or protective antigens against other pathogenic organisms (e.g., DTP, HBV, etc.).

[object Object]

Compositions comprising a first biological molecule from abacterium and a second biological molecule from abacterium. The term 'biological molecule' includes proteins and nucleic acids. Preferredspecies areand

Combination neisserial compositions

fHBP is a protein in. Three families of fHBP are known. To increase the ability of a fHBP protein to elicit antibodies that are cross-reactive between the families, fHBP is selected or engineered to have a sequence which can elicit broad-spectrum bactericidal anti-meningococcal antibodies after administration to a host animal.

Meningococcal fHBP polypeptides

Booster immunization can lead to rapid induction of protective immunity against pathogens (e.g. &#x2266;7 days after the booster dose). This rapid response means that booster immunization can be used at short notice prior to an event that might require an activated immune response. For instance, a subject can be primed at a young age against a pathogen that typically affects more elderly subjects under specific circumstances such that, when the subject is older, the immune response can be mobilized rapidly if those specific circumstances are expected. An example would be to prime a subject against infections that are typically acquired nosocomially and then, soon before a scheduled hospital appointment, to boost their immune response so that they enter hospital in an immune-alert state.

Rapid responses to delayed booster immunisations

The present invention relates to a medium containing non-animal derived proteinaceous material for cultivating patheogenic bacteria to produce an immunogenic factor and processes employing such medium.

Culture medium with yeast or soy bean extract as amino acid source and no protein complexes of animal origin

The invention provides proteins from, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.

Growing community of inventors

Siena, Italy

Rino Rappuoli